HUTCHMED reports Q4 2024 earnings and future plans

a discussion led by Michael Shi, our Chief Medical Officer, on research and development updates. HUTCHMED held its Q4 2024 earnings call today. The company's executives discussed financial results and provided insights into the future. David Ng, head of investor relations, opened the call by welcoming everyone and outlining the agenda. CEO Dr. Wei-Guo Su talked about the company's performance in 2024. He expressed optimism about HUTCHMED's pipeline of treatments and research initiatives. Following him, CFO Johnny Cheng shared details about the financial results for the year, highlighting revenues and expenses. George Yuan, the head of commercial, then reviewed HUTCHMED's commercial activities. He emphasized growth in demand for their products and services. Lastly, Chief Medical Officer Michael Shi discussed advancements in research and development, stressing the importance of ongoing studies. The call also included a reminder about future uncertainties. Executives noted that historical performance does not predict future results. The company remains focused on addressing risks that could impact its plans moving forward.